Biogen

Recent news

• RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Raises Target Price to $260
  Market Newswire · 2026/8/25
• Company notice
  Tanxin Biogen: Legal Opinion of Grandall Law Firm (Guangzhou) on the Adjustment of the Grant Price under Tanxin Biogen Co., Ltd.\'s 2024 Restricted Stock Incentive Plan
  SZSI · 2026/4/25
• Company notice
  Tanxin Biogen: Verification Opinion of CITIC Securities Co., Ltd. on the Delay of Certain Fund-Raising Investment Projects of Tanxin Biogen Co., Ltd.
  SZSI · 2026/3/21
• Piper Sandler Maintains Biogen(BIIB.US) With Buy Rating, Raises Target Price to $245
  Market Newswire · 2026/9/3
• Bernstein Initiates Biogen(BIIB.US) With Buy Rating, Announces Target Price $236
  Market Newswire · 2026/9/26
• Company notice
  Biogen | 3: Initial statement of beneficial ownership of securities- BIOGEN INC.
  SEC · 2026/4/7
• Wells Fargo Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $250
  Market Newswire · 2026/9/18
• Rating change
  Wolfe Research Upgrades Biogen(BIIB.US) to Buy Rating, Announces Target Price $300
  Market Newswire · 2026/8/14
• Rating change
  A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $215 to $255
  Market Newswire · 2026/7/31
• Rating change
  J.P. Morgan Maintains Biogen(BIIB.US) With Hold Rating, Raises Target Price to $210
  Market Newswire · 2026/7/31
• Rating change
  A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $215 to $256
  Market Newswire · 2026/7/30
• Rating change
  Citi Maintains Biogen(BIIB.US) With Hold Rating, Raises Target Price to $215
  Market Newswire · 2026/8/3
• Company notice
  Tanxin Biogen: Attestation Report by Huaxing Certified Public Accountants (Special General Partnership) on the Annual Custody, Management, and Use of Funds Raised by Tanxin Biogen Co., Ltd.
  SZSI · 2026/3/21
• Rating change
  Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating, Raises Target Price to $241
  Market Newswire · 2026/8/3
• Rating change
  HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $251
  Benzinga · 2026/7/31
• BMO Capital Maintains Biogen(BIIB.US) With Hold Rating
  Market Newswire · 2026/9/9
• Rating change
  Stifel Maintains Biogen(BIIB.US) With Buy Rating, Raises Target Price to $242
  Market Newswire · 2026/8/3
• Company notice
  Apellis Pharmaceuticals | 3: Initial statement of beneficial ownership of securities- BIOGEN INC.
  SEC · 2026/4/7

Headlines are aggregated automatically and are not independently verified or edited by our team.